Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 31, Issue 9, 2011, Pages 850-856

  Runyan, Courtney L ^a   Cabral, Katherine P ^a   Riker, Richard R ^a   Redding, David ^a   May, Teresa ^a   Seder, David B ^a   Savic, Marizela ^a   Hedlund, Jacqueline ^a   Abramson, Stuart ^a   Fraser, Gilles L ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Bivalirudin; Direct thrombin inhibitor; Heparin induced thrombocytopenia; HIT; Kidney dysfunction; Thrombosis

Indexed keywords

CREATININE; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; WARFARIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTINUOUS HEMOFILTRATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEMODIALYSIS; HEMOPTYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LEG THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MESENTERIC ARTERY THROMBOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; PARIETO-OCCIPITAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; SHOCK; STEADY STATE; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 80052200193     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.9.850     Document Type: Article

References (21)

1. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007;27:564-87. (Pubitemid 46536238)
2. Shantsila E, Lip GYH, Chong BH. Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest 2009;135:1651-64.
3. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. Chest 2008;133:S340-80.
4. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparininduced thrombocytopenia. Pharmacotherapy 2008;28:1115-24.
5. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparininduced thrombocytopenia. Pharmacotherapy 2006;26:461-8.
6. Skrupky LP, Smith JR, Arnold H, et al. Retrospective comparison of bivalirudin and argatroban in the management of heparin-induced thrombocytopenia [abstract]. Crit Care Med 2008;36(12 suppl):A175.
7. Francis JL, Drexler A, Moroose R. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparininduced thrombocytopenia [abstract]. Presented at the International Society on Thrombosis and Haemostasis XXth congress. Sydney, Australia, August 6-12, 2005.
8. Francis J, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia [abstract]. J Thromb Haemostasis 2003;1(suppl 1):abstract P1909.
9. Francis JL, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia [abstract]. Blood 2003;102:abstract 571.
10. Francis JL, Sandhu R, Drexler A, Dougherty J. Comparison of clinical outcomes in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibitors [abstract]. Blood 2004;103:abstract 3942.
11. Frame JN, Derreberry T, Davis EA, Wang Y. Bivalirudin in the treatment of patients with or at high-risk for heparin-induced thrombocytopenia [abstract]. Blood 2006;108:abstract 4120.
12. Berligen JE, Nguyen PH, Baker KR. Bivalirudin in the treatment of heparin-induced thrombocytopenia [abstract]. Blood 2003;102:abstract 1969.
13. Skrupky LP, Smith JR, Deal EN, et al. Comparison of bivalirudin and argatroban for the management of heparininduced thrombocytopenia. Pharmacotherapy 2010:30: 1229-38.
14. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12(suppl F):F33-6.
15. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121: 535-55. (Pubitemid 36645375)
16. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients: Scientific and Standardization Committee Communication. J Thromb Haemost 2005:3:692-4. (Pubitemid 41647882)
17. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26: 452-60.
18. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban on prothrombin time and INR values. Am J Clin Pathol 2004;121: 593-9. (Pubitemid 38392969)
19. Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004;30:359-68. (Pubitemid 39037630)
20. Chan M, Malynn E, Shaz B, Uhl L. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol 2008;83:212-17. (Pubitemid 351303945)
21. Zwicker JI, Uhl L, Huang W-Y, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-7. (Pubitemid 40185772)